{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:33:04Z","timestamp":1786116784557,"version":"build-2736575974"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82374090"],"award-info":[{"award-number":["82374090"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003787","name":"Natural Science Foundation of Hebei Province","doi-asserted-by":"publisher","award":["223777157D"],"award-info":[{"award-number":["223777157D"]}],"id":[{"id":"10.13039\/501100003787","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003787","name":"Natural Science Foundation of Hebei Province","doi-asserted-by":"publisher","award":["H2026206048"],"award-info":[{"award-number":["H2026206048"]}],"id":[{"id":"10.13039\/501100003787","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Resistance Updates"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.drup.2026.101439","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T23:39:22Z","timestamp":1782517162000},"page":"101439","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Tailored HER2 ECD mRNA-LNP vaccines boost CD8+ T cell-mediated antitumor immunity for HER2-positive tumor suppression"],"prefix":"10.1016","volume":"88","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1201-2810","authenticated-orcid":false,"given":"Kexin","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zilin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoya","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuping","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyu","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yating","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guogui","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongtao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5854-9827","authenticated-orcid":false,"given":"Lianmei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drup.2026.101439_bib1","first-page":"737","article-title":"A new combination of 5\u2032- and 3\u2032-untranslated regions increases the expression of mRNAs in vitro and in vivo","volume":"29","author":"Antropov","year":"2025","journal-title":"Vavilovskii Zh Genet. i Sel."},{"key":"10.1016\/j.drup.2026.101439_bib2","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005923","article-title":"Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with targeted therapies","volume":"11","author":"Atkins","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.drup.2026.101439_bib3","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1038\/nprot.2007.173","article-title":"Collagen-induced arthritis","volume":"2","author":"Brand","year":"2007","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.drup.2026.101439_bib4","doi-asserted-by":"crossref","first-page":"4128","DOI":"10.1038\/s41467-020-17981-0","article-title":"Strength of immune selection in tumors varies with sex and age","volume":"11","author":"Castro","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.drup.2026.101439_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2025.102687","article-title":"The potential and challenges of circular RNA in the development of vaccines and drugs for emerging infectious diseases","volume":"36","author":"Chen","year":"2025","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.drup.2026.101439_bib6","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1002\/path.4742","article-title":"T cell receptor \u03b2-chain repertoire analysis reveals intratumour heterogeneity of tumour-infiltrating lymphocytes in oesophageal squamous cell carcinoma","volume":"239","author":"Chen","year":"2016","journal-title":"J. Pathol."},{"key":"10.1016\/j.drup.2026.101439_bib7","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.4049\/jimmunol.137.6.1845","article-title":"Immune response gene control of lymphocyte proliferation induced by acetylcholine receptor-specific helper factor derived from lymphocytes of myasthenic mice","volume":"137","author":"Christadoss","year":"1986","journal-title":"Journal immunology (Baltimore Md 1950)"},{"key":"10.1016\/j.drup.2026.101439_bib8","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.ccell.2024.02.004","article-title":"Retinoic acid receptor activation reprograms senescence response and enhances anti-tumor activity of natural killer cells","volume":"42","author":"Colucci","year":"2024","journal-title":"Cancer Cell."},{"key":"10.1016\/j.drup.2026.101439_bib9","article-title":"Results of a Phase Ib Trial of Combination Immunotherapy with a CD8+ T Cell Eliciting Vaccine and Trastuzumab in Breast Cancer Patients","volume":"24","author":"G Travis","year":"2017","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.drup.2026.101439_bib10","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/s41571-025-01059-1","article-title":"Understanding and overcoming multidrug resistance in cancer","volume":"22","author":"Ge","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.drup.2026.101439_bib11","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/s41568-023-00615-0","article-title":"Stem-like exhausted and memory CD8(+) T cells in cancer","volume":"23","author":"Gebhardt","year":"2023","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.drup.2026.101439_bib12","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41541-025-01097-x","article-title":"Recent advances and perspectives on the development of circular RNA cancer vaccines","volume":"10","author":"Gong","year":"2025","journal-title":"NPJ Vaccin."},{"key":"10.1016\/j.drup.2026.101439_bib13","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1016\/j.vaccine.2022.03.014","article-title":"Immunogenicity of a xenogeneic multi-epitope HER2 breast cancer DNA vaccine targeting the dendritic cell restricted antigen-uptake receptor DEC205","volume":"40","author":"G\u00fcl","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.drup.2026.101439_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.110214","article-title":"The interactions of docetaxel with tumor microenvironment","volume":"119","author":"Gupta","year":"2023","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.drup.2026.101439_bib15","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.immuni.2019.12.011","article-title":"Top 10 Challenges in Cancer Immunotherapy","volume":"52","author":"Hegde","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.drup.2026.101439_bib16","doi-asserted-by":"crossref","first-page":"4009","DOI":"10.1182\/blood-2006-04-015024","article-title":"Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells","volume":"108","author":"Holtkamp","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.drup.2026.101439_bib17","article-title":"ErbB receptors: from oncogenes to targeted cancer therapies","volume":"117","author":"Hongtao","year":"2007","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.drup.2026.101439_bib18","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000342","article-title":"Globo H-KLH vaccine adagloxad simolenin (OBI-822)\/OBI-821 in patients with metastatic breast cancer: phase II randomized, placebo-controlled study","volume":"8","author":"Huang","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.drup.2026.101439_bib19","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMra043186","article-title":"Trastuzumab--mechanism of action and use in clinical practice","volume":"357","author":"Hudis","year":"2007","journal-title":"New. Engl. J. Med."},{"key":"10.1016\/j.drup.2026.101439_bib20","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41416-019-0635-y","article-title":"Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer","volume":"122","author":"Hunter","year":"2020","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.drup.2026.101439_bib21","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/nm0795-644","article-title":"Prevention of breast tumour development in vivo by downregulation of the p185neu receptor","volume":"1","author":"Katsumata","year":"1995","journal-title":"Nat. Med."},{"key":"10.1016\/j.drup.2026.101439_bib22","first-page":"86","article-title":"A review of cancer immunotherapy toxicity","volume":"70","author":"Kennedy","year":"2020","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.drup.2026.101439_bib23","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1146\/annurev-biochem-060614-034402","article-title":"A structural perspective on the regulation of the epidermal growth factor receptor","volume":"84","author":"Kovacs","year":"2015","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.drup.2026.101439_bib24","article-title":"Robust CD8(+) T cell responses induced by an mRNA-LNP vaccine encoding rat HER2 extracellular domain confer prophylactic tumor protection","volume":"17","author":"Li","year":"2026","journal-title":"Front. Immunol."},{"key":"10.1016\/j.drup.2026.101439_bib25","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12943-024-02023-w","article-title":"Regulatory mechanisms of PD-1\/PD-L1 in cancers","volume":"23","author":"Lin","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.drup.2026.101439_bib26","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41591-024-03334-7","article-title":"Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial","volume":"31","author":"Lopez","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.drup.2026.101439_bib27","article-title":"How TCRs bind MHCs, peptides, and coreceptors","volume":"24","author":"Markus","year":"2006","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.drup.2026.101439_bib28","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1093\/annonc\/mdu211","article-title":"Final report of the phase I\/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients","volume":"25","author":"Mittendorf","year":"2014","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.drup.2026.101439_bib29","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJMoa2200674","article-title":"Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine","volume":"386","author":"Moreira","year":"2022","journal-title":"New. Engl. J. Med."},{"key":"10.1016\/j.drup.2026.101439_bib30","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2103730118","article-title":"Critical role of the CD44(low)CD62L(low) CD8(+) T cell subset in restoring antitumor immunity in aged mice","volume":"118","author":"Nakajima","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.drup.2026.101439_bib31","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aaz6893","article-title":"Impact of mRNA chemistry and manufacturing process on innate immune activation","volume":"6","author":"Nelson","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.drup.2026.101439_bib32","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1158\/1078-0432.CCR-13-2663","article-title":"Chimeric Rat\/Human HER2 Efficiently Circumvents HER2 Tolerance in Cancer Patients","volume":"20","author":"Occhipinti","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drup.2026.101439_bib33","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines - a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat. Rev. Drug. Discov."},{"key":"10.1016\/j.drup.2026.101439_bib34","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines \u2014 a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat. Rev. Drug. Discov."},{"key":"10.1016\/j.drup.2026.101439_bib35","article-title":"AE37: a HER2-targeted vaccine for the prevention of breast cancer recurrence","volume":"30","author":"Patrick","year":"2020","journal-title":"Expert. Opin. Investig. Drugs"},{"key":"10.1016\/j.drup.2026.101439_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.21873\/anticanres.14746","article-title":"Chemoradiotherapy in Cancer Treatment: Rationale and Clinical Applications","volume":"41","author":"Rallis","year":"2021","journal-title":"Anticancer. Res."},{"key":"10.1016\/j.drup.2026.101439_bib37","doi-asserted-by":"crossref","first-page":"519","DOI":"10.2217\/imt.14.22","article-title":"The HER2 peptide nelipepimut-S (E75) vaccine (NeuVax\u2122) in breast cancer patients at risk for recurrence: correlation of immunologic data with clinical response","volume":"6","author":"Schneble","year":"2014","journal-title":"Immunotherapy"},{"key":"10.1016\/j.drup.2026.101439_bib38","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1038\/s41586-024-08508-4","article-title":"RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer","volume":"639","author":"Sethna","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.drup.2026.101439_bib39","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The future of immune checkpoint therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Science (New York NY)"},{"key":"10.1016\/j.drup.2026.101439_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2023.115175","article-title":"The immunostimulatory nature of mRNA lipid nanoparticles","volume":"205","author":"Sharma","year":"2024","journal-title":"Adv. Drug. Deliv. Rev."},{"key":"10.1016\/j.drup.2026.101439_bib41","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.ccell.2023.03.014","article-title":"Phenotypic plasticity and reduced tissue retention of exhausted tumor-infiltrating T cells following neoadjuvant immunotherapy in head and neck cancer","volume":"41","author":"Sievers","year":"2023","journal-title":"Cancer Cell."},{"key":"10.1016\/j.drup.2026.101439_bib42","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41573-022-00579-0","article-title":"Targeting HER2-positive breast cancer: advances and future directions","volume":"22","author":"SM","year":"2023","journal-title":"Nat. Rev. Drug. Discov."},{"key":"10.1016\/j.drup.2026.101439_bib43","doi-asserted-by":"crossref","first-page":"6023","DOI":"10.1093\/nar\/gkx135","article-title":"N1-methyl-pseudouridine in mRNA enhances translation through eIF2\u03b1-dependent and independent mechanisms by increasing ribosome density","volume":"45","author":"Svitkin","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.drup.2026.101439_bib44","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41573-022-00579-0","article-title":"Targeting HER2-positive breast cancer: advances and future directions","volume":"22","author":"Swain","year":"2023","journal-title":"Nat. Rev. Drug. Discov."},{"key":"10.1016\/j.drup.2026.101439_bib45","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","article-title":"Immune checkpoint blockade: a common denominator approach to cancer therapy","volume":"27","author":"Topalian","year":"2015","journal-title":"Cancer Cell."},{"key":"10.1016\/j.drup.2026.101439_bib46","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.131882","article-title":"CD47 blockade augmentation of trastuzumab antitumor efficacy dependent on antibody-dependent cellular phagocytosis","volume":"4","author":"Tsao","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.drup.2026.101439_bib47","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.ccell.2023.05.009","article-title":"Taxanes trigger cancer cell killing in vivo by inducing non-canonical T cell cytotoxicity","volume":"41","author":"Vennin","year":"2023","journal-title":"Cancer Cell."},{"key":"10.1016\/j.drup.2026.101439_bib48","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/j.immuni.2022.10.014","article-title":"Innate immune mechanisms of mRNA vaccines","volume":"55","author":"Verbeke","year":"2022","journal-title":"Immunity"},{"key":"10.1016\/j.drup.2026.101439_bib49","doi-asserted-by":"crossref","first-page":"3649","DOI":"10.1158\/1078-0432.CCR-20-3742","article-title":"Clinical and Immunologic Responses to a B-Cell Epitope Vaccine in Patients with HER2\/neu-Overexpressing Advanced Gastric Cancer-Results from Phase Ib Trial IMU.ACS.001","volume":"27","author":"Wiedermann","year":"2021","journal-title":"Clinical cancer research official journal American Association Cancer Research"},{"key":"10.1016\/j.drup.2026.101439_bib50","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1038\/s41467-020-15679-x","article-title":"Sex-associated molecular differences for cancer immunotherapy","volume":"11","author":"Ye","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.drup.2026.101439_bib51","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/s41586-023-06753-7","article-title":"Repeated Omicron exposures override ancestral SARS-CoV-2 immune imprinting","volume":"625","author":"Yisimayi","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.drup.2026.101439_bib52","article-title":"Chronic Psychological Stress Activates TRP\/TAM\/CXCL1 Signaling to Promote Breast Cancer Adipocyte Lipolysis via KEAP1 m(6)A Demethylation","volume":"8","author":"Zhan","year":"2025","journal-title":"Res. (Wash. DC)"},{"key":"10.1016\/j.drup.2026.101439_bib53","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/s41551-025-01344-5","article-title":"Small circular RNAs as vaccines for cancer immunotherapy","volume":"9","author":"Zhang","year":"2025","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.drup.2026.101439_bib54","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/s41541-023-00751-6","article-title":"Effect of mRNA-LNP components of two globally-marketed COVID-19 vaccines on efficacy and stability","volume":"8","author":"Zhang","year":"2023","journal-title":"NPJ Vaccin."},{"key":"10.1016\/j.drup.2026.101439_bib55","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.70031","article-title":"Combined pyrotinib and fulvestrant for hormone receptor-positive and HER2-positive metastatic breast cancer: A multicenter, single-arm, phase II trial","volume":"6","author":"Zhao","year":"2025","journal-title":"MedComm"},{"key":"10.1016\/j.drup.2026.101439_bib56","article-title":"HED, a Human-Engineered Domain, Confers a Unique Fc-Binding Activity to Produce a New Class of Humanized Antibody-like Molecules","volume":"24","author":"Zhiqiang","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.drup.2026.101439_bib57","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13046-026-03640-7","article-title":"Circular RNA-based HPV16 therapeutic vaccine elicits potent and durable antitumor immunity","volume":"45","author":"Zhou","year":"2026","journal-title":"J. Exp. & Clin. Cancer Res."},{"key":"10.1016\/j.drup.2026.101439_bib58","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13045-025-01670-w","article-title":"Cancer vaccines: current status and future directions","volume":"18","author":"Zhou","year":"2025","journal-title":"J. Hematol. & Oncol."},{"key":"10.1016\/j.drup.2026.101439_bib59","article-title":"crVDAC3 alleviates ferroptosis by impeding HSPB1 ubiquitination and confers trastuzumab deruxtecan resistance in HER2-low breast cancer","volume":"77","author":"Zou","year":"2024","journal-title":"Drug. Resist. Update. Rev. Comment. Antimicrob. Anticancer. Chemother."}],"container-title":["Drug Resistance Updates"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1368764626000907?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1368764626000907?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T11:58:27Z","timestamp":1786017507000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1368764626000907"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":59,"alternative-id":["S1368764626000907"],"URL":"https:\/\/doi.org\/10.1016\/j.drup.2026.101439","relation":{},"ISSN":["1368-7646"],"issn-type":[{"value":"1368-7646","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tailored HER2 ECD mRNA-LNP vaccines boost CD8+ T cell-mediated antitumor immunity for HER2-positive tumor suppression","name":"articletitle","label":"Article Title"},{"value":"Drug Resistance Updates","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drup.2026.101439","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101439"}}